GRDN Guardian Pharmacy Services, Inc
$43.64▼ -0.43%
Healthcare
Other
After hours
$43.64▲ +0.00%
Sep 11, 4:29 PM ET
Volume 923.2K
Avg Volume (10D) 487.9K
Key Metrics & Fundamentals
Market Cap
$2.76B
P/E Ratio
42.0
Div Yield
–%
52W Range
23.14 - 47.02
% vs 50 MA
9.14%
% vs 200 MA
20.94%
RSI-14
69.5
MACD Histogram
+0.7700
Beta (1Y vs SPY)
0.67
Free Cash Flow
$25.41M
Gross Rev
$351.77M
Gross Profit
$80.04M
EBITDA
$35.75M
COGS
$271.72M
Operating Exp
$59.40M
Operating Income
$20.64M
EBIT
$20.64M
Pretax Income
$29.79M
Net Income
$21.87M
EPS (Diluted)
0.34
Price & Volume History
Loading chart…
Recent News
Guardian Pharmacy Services Buys Assets From Nautilus Pharmacy
MT Newswires · Sep 1, 2026 8:57 PM
Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy
Business Wire · Sep 1, 2026 8:30 PM
Guardian Pharmacy Services, Inc., to Participate in Upcoming Jefferies Healthcare Services Investor Conference
Business Wire · Aug 19, 2026 8:30 PM
Guardian Pharmacy Services (GRDN) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 13, 2026 11:44 PM
Guardian Pharmacy Services (GRDN) As Strong Results And Higher Outlook Recast The Valuation Story
Simply Wall St. · Aug 9, 2026 5:08 PM
Why Guardian Pharmacy Services (GRDN) Is Up 10.9% After Raising 2026 Revenue Guidance And Expanding Footprint
Simply Wall St. · Aug 8, 2026 10:11 PM
Guardian Pharmacy Services Q2 Earnings Call Highlights
MarketBeat · Aug 8, 2026 10:03 AM
Oppenheimer Adjusts PT on Guardian Pharmacy Services to $49 From $43, Maintains Outperform Rating
MT Newswires · Aug 7, 2026 1:17 PM
Guardian Pharmacy Services Raises 2026 Outlook After Strong Second Quarter
InvestorsHub · Aug 7, 2026 12:46 PM
Guardian Pharmacy Services Inc (GRDN) (Q2 2026) Earnings Call Highlights: Raised Guidance and ...
GuruFocus.com · Aug 7, 2026 5:06 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See GRDN's money flow as a full page
Social Sentiment
Avg +1.00 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.